Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fomitopsis cajanderi hot aqueous extract is a research-stage natural product extract derived from the fruiting body of the *Fomitopsis cajanderi* mushroom, commonly known as the Rosy Polypore. Prepared via a two-hour decoction in water at 100°C, the extract is primarily composed of immunomodulatory beta-glucans (polysaccharides). It has been studied in vitro for its potential anti-inflammatory, immunomodulatory, and anticancer properties. Specifically, the extract exhibits concentration-dependent cytotoxic effects on human U-937 histiocytic lymphoma cells and inhibits tumor necrosis factor (TNF) secretion by lipopolysaccharide (LPS)-stimulated U-937 monocytes. It also potentially modulates other cytokines such as interferon-gamma (IFN-γ) and interleukin-2 (IL-2). Currently, the extract remains in the academic research stage with no commercial development or clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fomitopsis cajanderi hot aqueous extract.